Skip to Content

Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasia

The Department of Leukemia has established the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasia (HAP-CRC-MPN) as a distinct operational unit within the Leukemia Department and Leukemia Outpatient Center. The goal of this clinical research center is to develop a comprehensive approach to understanding the biology of myeloproliferative neoplasms through translational research, leading to new and effective therapies for myeloproliferative disorders.

Under the guidance of Dr. Srdan Verstovsek, Chief of the Section of Myeloproliferative Neoplasms, MD Anderson has become the largest center in the world for MPN patient referral and research. We see annually more than 250 new patients with MPN, far more than any other clinical center in the world, and are engaged continuously in clinical research (conduct of clinical studies) to try to find effective therapies. Nothing of similar proportion exists anywhere in the world.

Components of the HAP-CRC-MPN include:

  • Clinical trials with novel agents developed specifically for patients with MPN
  • Centralized tissue bank and database for collection and annotation of patient samples
  • Education of physicians, patients and their families about the latest in research and treatment of MPNs

Myeloproliferative Neoplasms

Myeloproliferative neoplasias (also known as myeloproliferative diseases) have been traditionally divided into two groups: classic and atypical.  

Classic MPNs include:

  • Essential thrombocythemia (ET)
  • Polycythemia vera (PV)
  • Primary myelofibrosis (PMF)

Atypical MPNs include:

  • Juvenile myelomonocytic leukemia (JMML)
  • Systemic mastocytosis (SM)
  • Chronic Eosinophilic Leukemia/Hypereosinophilic Syndrome (HES)

Classic MPNs are characterized by overproduction of cells in the bone marrow, leading to too many cells in the bloodstream. Each year about 20,000 new patients are diagnosed with classic MPN. The total number of patients with myeloproliferative disorders in the United States is estimated to be about 250,000. The average age of patients at diagnosis is 60-65 years, but the diseases spare no age group. Life expectancy varies from decades for patients with ET and PV to only 5-7 years for those with PMF.

While new therapies are improving symptoms and outcomes, no therapy has been shown to eradicate the disease. However, Dr. Verstovsek is the Principal Investigator on several clinical studies testing new treatments for these diseases.


© 2014 The University of Texas MD Anderson Cancer Center